HEALTH Enhancement Products Inc. (HEPI), a Michigan-based natural product developer, announced that it was advised by the U.S. Patent Office that a patent will be issued for Application No. 12/067,735, "Composition & Use of Phyto-Percolate for Treatment of Disease," thereby establishing HEPI's claims on novel methods of producing and administering products derived from its proprietary algal cultures.
In related news, HEPI directed the Arizona office of the law firm of Snell & Wilmer to file a new provisional patent application that potentially expands the use of its proprietary phyto-percolate and derivative compounds to animal health uses, specifically addressing bovine mastitis, bovine respiratory disease complex, transition cow syndrome, porcine reproductive and respiratory syndrome and canine osteoarthritis — primarily autoimmune and metabolic disorders, the announcement said.
The application was prompted by recent genetic tests that revealed certain signaling pathways and gene activation utilizing RNA from an ongoing bovine mastitis study conducted by Dr. Laura Hernandez, a lactation expert and faculty member at the University of Wisconsin-Madison.
Hernandez has been conducting in vitro work with isolated samples of HEPI's proprietary bioactive compounds and their effects on primary bovine mammary epithelial cells exposed to inflammatory and infective agents.
HEPI noted that it has requested that the University of Wisconsin assess the viability of a urine-based bovine stress and metabolic test, which would profile animals susceptible to stress-induced conditions that may then progress into infectious diseases or autoimmune disorders. The provisional patent application for such a test was filed June 14 by Kohn & Associates Inc., a patent law firm based in Michigan.
HEPI is engaged in the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologics for medicinal and pharmaceutical applications in people and animals.